REG - OptiBiotix Health - Directorate Change

OptiBiotix HealthAnnouncement

23/10/2024 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241023:nRSW2080Ja&default-theme=true

RNS Number : 2080J  OptiBiotix Health PLC  23 October 2024

OptiBiotix Health plc

("OptiBiotix" or the "Company" or "the Group")

 

Directorate change

 

OptiBiotix Health plc ("OptiBiotix") announces that Graham Myers, Finance
Director of the Company, has notified the Company that he will step down from
the Board on 30 November 2024.

 

David Blain will join the Company as acting Finance Director on 1 November
2024. Mr Blain's appointment to the Board of the Company will be subject to
normal regulatory due diligence.

 

David is a member of ICAEW and has extensive financial, commercial and Board
experience in a number of private and public companies, including Iksuda
Therapeutics Ltd, Applied Graphene Materials plc, Nanoco Group plc and
Inspired Capital plc (formerly Renovo Group plc). Mr Blain is currently
Financial Director (non-board position) at Iksuda Therapeutics Ltd.

 

The Company notes recent speculation in relation to the health of the
Company's Chief Executive Officer Stephen O'Hara.  Mr O'Hara is recovering
after a short illness and expects to be back at work shortly.

 

Neil Davidson, Chairman of OptiBiotix Health plc said: "On behalf of the
Board, I would like to thank Graham for his contribution to the Company over
the last year and welcome David as we move to our next stage of growth."

 

 

 For further information, please contact: OptiBiotix Health plc      www.optibiotix.com (http://www.optibiotix.com/)
 Neil Davidson, Chairman           Contact via Walbrook below
 Stephen O'Hara, Chief Executive

 Cairn Financial Advisers LLP (NOMAD)                                Tel: 020 7213 0880
 Liam Murray / Jo Turner / Ludovico Lazzaretti

 Peterhouse Capital Limited (Broker)                                 Tel: 020 7220 9797
 Duncan Vasey / Lucy Williams

 Walbrook PR Ltd                                                     Mob: 07876 741 001
 Anna Dunphy

 

About OptiBiotix - www.optibiotix.com (http://www.optibiotix.com/)

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings
science to the development of compounds which modify the human microbiome -
the collective genome of the microbes in the body - in order to prevent and
manage human disease and promote wellness.

 

OptiBiotix has an extensive R&D programme working with leading academics
in the development of microbial strains, compounds, and formulations which are
used as active ingredients and supplements. More than twenty international
food and healthcare supplement companies have signed agreements with
OptiBiotix to incorporate their human microbiome modulators into a wide range
of food products and drinks.

 

OptiBiotix is also developing its own range of consumer supplements and health
products. The Company's current areas of focus include obesity, cardiovascular
health, and diabetes.

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAFLLLLZBLXFBD